646 related articles for article (PubMed ID: 29317800)
1. Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M; Farhoudi R
Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for leishmaniasis: from proteome to vaccine candidates.
Schroeder J; Aebischer T
Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
[TBL] [Abstract][Full Text] [Related]
3. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
4. How to master the host immune system? Leishmania parasites have the solutions!
Rossi M; Fasel N
Int Immunol; 2018 Mar; 30(3):103-111. PubMed ID: 29294040
[TBL] [Abstract][Full Text] [Related]
5. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
[TBL] [Abstract][Full Text] [Related]
6. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
7. Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
Duthie MS; Reed SG
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515135
[TBL] [Abstract][Full Text] [Related]
8. Leishmaniasis and various immunotherapeutic approaches.
Taslimi Y; Zahedifard F; Rafati S
Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
[TBL] [Abstract][Full Text] [Related]
9. Identifying vaccine targets for anti-leishmanial vaccine development.
Sundar S; Singh B
Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
[TBL] [Abstract][Full Text] [Related]
11. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
Seyed N; Peters NC; Rafati S
Front Immunol; 2018; 9():1227. PubMed ID: 29922288
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs.
Rajasekaran R; Chen YP
Drug Discov Today; 2015 Aug; 20(8):958-68. PubMed ID: 25936844
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
14. Treatment of leishmaniasis: a review and assessment of recent research.
Elmahallawy EK; Agil A
Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
[TBL] [Abstract][Full Text] [Related]
15. Arsenite resistance in Leishmania and possible drug targets.
Singh G; Jayanarayan KG; Dey CS
Adv Exp Med Biol; 2008; 625():1-8. PubMed ID: 18365654
[TBL] [Abstract][Full Text] [Related]
16. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
17. Leishmania lipophosphoglycan components: A potent target for synthetic neoglycoproteins as a vaccine candidate for leishmaniasis.
Mohammed ASA; Tian W; Zhang Y; Peng P; Wang F; Li T
Carbohydr Polym; 2020 Jun; 237():116120. PubMed ID: 32241437
[TBL] [Abstract][Full Text] [Related]
18. Leishmania vaccine development: A comprehensive review.
Saini I; Joshi J; Kaur S
Cell Immunol; 2024; 399-400():104826. PubMed ID: 38669897
[TBL] [Abstract][Full Text] [Related]
19. Leishmania vaccine development: exploiting the host-vector-parasite interface.
Reed SG; Coler RN; Mondal D; Kamhawi S; Valenzuela JG
Expert Rev Vaccines; 2016; 15(1):81-90. PubMed ID: 26595093
[TBL] [Abstract][Full Text] [Related]
20. Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.
Mendonça SC
Parasit Vectors; 2016 Sep; 9(1):492. PubMed ID: 27600664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
